Lactoferrin dampens high-fructose corn syrup-induced hepatic manifestations of the metabolic syndrome in a murine model

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Li, Yi Chieh ^a   Hsieh, Chang Chi ^a  

^a TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; CHOLESTEROL; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; LACTOFERRIN; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMIC STROMAL LYMPHOPOIETIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE; CORN SYRUP; CYTOKINE; LIPOPOLYSACCHARIDE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL SYNTHESIS; CIRCULATION; CONTROLLED STUDY; FATTY LIVER; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER DISEASE; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; ORGAN WEIGHT; OXIDATIVE STRESS; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; PHYSIOLOGY;

ADIPOKINES; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; HIGH FRUCTOSE CORN SYRUP; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LACTOFERRIN; LIPOPOLYSACCHARIDES; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES;

EID: 84901207710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097341     Document Type: Article

References (53)

1. Baranova A, Randhawa M, Jarrar M, Younossi ZM (2007) Adipokines and melanocortins in the hepatic manifestation of the metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn 7: 195-205. (Pubitemid 46513445)
2. Castro GS, Cardoso JF, Vannucchi H, Zucoloto S, Jordão AA (2011) Fructose and NAFLD: metabolic implications and models of induction in rats. Acta Cir Bras 26 Suppl 2: 45-50.
3. Saito T, Misawa K, Kawata S (2007) 1. Fatty liver and non-alcoholic steatohepatitis. Intern Med 46: 101-103.
4. Basciano H, Federico L, Adeli K (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2: 1-14
5. Rutledge AC, Adeli K (2007) Fructose and the the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev 2007 65(6 Pt 2): S13-23.
6. Nseir W, Nassar F, Assy N (2010) Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 16: 2579-2588.
7. Cook GC (1969) Absorption products of D(-) fructose in man. Clin Sci 37: 675-687.
8. Hsu CS, Kao JH (2012) Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc 111: 527-535.
9. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology. 114: 842-845.
10. Keidar S, Kaplan M, Rosenblat M, Brook GJ, Aviram M (1992) Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized very-low-density lipoprotein (VLDL), but increase cellular degradation of native VLDL. Metabolism 41: 1185-1192.
11. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, et al. (2001) Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35: 279-283. (Pubitemid 32803485)
12. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F (2001) Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 35: 307-307.
13. Brock JH (2002) The physiology of lactoferrin. Biochem Cell Biol 80: 1-6.
14. Petschow BW, Talbott RD, Batema RP (1999) Ability of lactoferrin to promote the growth of Bifidobacterium spp. in vitro is independent of receptor binding capacity and iron saturation level. J Med Microbiol 48: 541-549. (Pubitemid 29476459)
15. Sherman MP, Bennett SH, Hwang FF, Yu C (2004) Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals 17: 285-289. (Pubitemid 38987151)
16. Valenti P, Antonini G (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62: 2576-2587. (Pubitemid 41721231)
17. Takeuchi T, Shimizu H, Ando K, Harada E (2004) Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents. Br J Nutr 91: 533-538. (Pubitemid 38584777)
18. Morishita S, Ono T, Fujisaki C, Ishihara Y, Murakoshi M, et al. (2013) Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice. J Oleo Sci 62: 97-103.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. (Pubitemid 40770284)
21. Fiorini RN, Kirtz J, Periyasamy B, Evans Z, Haines JK, et al. (2004) Development of an unbiased method for the estimation of liver steatosis. Clin Transplant 18: 700-706. (Pubitemid 39496984)
22. Yang J, Ren J, Song J, Liu F, Wu C, et al. (2013) Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int J Mol Med. 31: 1429-1435.
23. Hsieh CC, Fang HL, Lin WC (2008) Inhibitory effect of Solanum nigrum on thioacetamide-induced liver fibrosis in mice. J Ethnopharmacol 119: 117-121.
24. Blakely SR, Hallfrisch J, Reiser S, Prather ES (1981) Long-term effects of moderate fructose feeding on glucose tolerance parameters in rats. J Nutr 111: 307-314. (Pubitemid 11148434)
25. Beck-Nielsen H, Pedersen O, Lindskov HO (1980) Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr 33: 273-278. (Pubitemid 10152933)
26. Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28: 68-76.
27. Takeuchi T, Kitagawa H, Harada E (2004) Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89: 263-270. (Pubitemid 38660039)
28. Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, et al. (2013) High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 58: 1632-1643.
29. Fernández-Musoles R, Castelló-Ruiz M, Arce C, Manzanares P, Ivorra MD, et al. (2014) Antihypertensive Mechanism of Lactoferrin-Derived Peptides: Angiotensin Receptor Blocking Effect. J Agric Food Chem. 62: 173-181.
30. Rytilä P, Rehn T, Ilumets H, Rouhos A, Sovijärvi A, et al. (2006) Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 7: 1-10.
31. Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W, Fernández- Real JM (2009) Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab 94: 4036-4044.
32. Spruss A, Bergheim I (2009) Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 20: 657-662.
33. Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, et al. (1996) Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 40: 257-262. (Pubitemid 26249678)
34. Baeuerle PA (1998) Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 8: R19-22.
35. Håversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I (2002) Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220: 83-95. (Pubitemid 36349060)
36. Puddu P, Latorre D, Carollo M, Catizone A, Ricci G, et al. (2011) Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS ONE 6: e22504.
37. Yamauchi K, Tomita M, Giehl TJ, Ellison RT III (1993) Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 61: 719-728. (Pubitemid 23030865)
38. Ellison RT III, Giehl TJ, LaForce FM (1988) Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56: 2774-2781. (Pubitemid 18259927)
39. Chapple DS, Hussain R, Joannou CL, Hancock RE, Odell E, et al. (2004) Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob Agents Chemother 48: 2190-2198. (Pubitemid 38691618)
40. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M (1992) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73: 472-479.
41. Chapple DS, Joannou CL, Mason DJ, Shergill JK, Odell EW, et al. (1998) A helical region on human lactoferrin. Its role in antibacterial pathogenesis. Adv Exp Med Biol 443: 215-220. (Pubitemid 28432188)
42. Farnaud S, Patel A, Odell EW, Evans RW (2004) Variation in antimicrobial activity of lactoferricin-derived peptides explained by structure modelling. FEMS Microbiol Lett 238: 221-226. (Pubitemid 39164552)
43. Chapple DS, Mason DJ, Joannou CL, Odell EW, Gant V, et al. (1998) Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect Immun 66: 2434-2440. (Pubitemid 28261735)
44. Elass-Rochard E, Roseanu A, Legrand D, Trif M, Salmon V, et al. (1995) Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J 312: 839-845. (Pubitemid 26005997)
45. Xu G, Xiong W, Hu Q, Zuo P, Shao B, et al. (2010) Lactoferrin-derived peptides and Lactoferricin chimera inhibit virulence factor production and biofilm formation in Pseudomonas aeruginosa. J Appl Microbiol 109:1311-1318.
46. Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M, et al. (2007) Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int Immunopharmacol 7: 1387-1393. (Pubitemid 47161068)
47. Mjösberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, et al. (2012) The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37: 649-659.
48. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, et al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301.
49. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14: 561-566. (Pubitemid 41623184)
50. Wanninger J, Bauer S, Eisinger K, Weiss TS, Walter R, et al. (2012) Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol 349: 248-254.
51. An L, Wang X, Cederbaum AI (2012) Cytokines in alcoholic liver disease. Arch Toxicol 86: 1337-1348.
52. Feng B, Jiao P, Nie Y, Kim T, Jun D, et al. (2011) Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. PLoS ONE 6: e24358.
53. Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, et al. (2013) Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62: 1623-1632.